Use of a cannabinoid receptor agonist for the treatment of gastroesophageal reflux disease

摘要

Disclosed is the use of cannabinoid receptor agonists for the manufacture of medicaments for the inhibition of transient lower esophageal sphincter relaxations (TLESRs), for the treatment of gastroesophageal reflux disease (GERD), reflux, regurgitation and managing failure to thrive.